First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.
暂无分享,去创建一个
M. Woodward | K. Ismail | David Hopkins | R. Holt | D. Hopkins | R. Holt | R. Peveler | M. Smith
[1] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.
[2] Donald R. Miller,et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. , 2006, American journal of epidemiology.
[3] R. Holt,et al. Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria , 2006, Diabetologia.
[4] D. Cohen,et al. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment , 2006, European Neuropsychopharmacology.
[5] E. Tafesse,et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case‐control study of California Medicaid claims , 2005, Pharmacoepidemiology and drug safety.
[6] Ronald R. Brown,et al. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine , 2005, International clinical psychopharmacology.
[7] A. Young,et al. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study , 2005, Diabetologia.
[8] M. Miller,et al. Prevalence of diabetes mellitus in patients receiving depot neuroleptics or clozapine. , 2005, Archives of psychiatric nursing.
[9] G. Mazzaglia,et al. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure , 2005, International clinical psychopharmacology.
[10] J. Levine,et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. , 2004, Psychiatric services.
[11] R. Rosenheck,et al. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. , 2004, The American journal of psychiatry.
[12] J. Ananth,et al. Side effects of atypical antipsychotic drugs. , 2004, Current pharmaceutical design.
[13] C. Byrne,et al. Schizophrenia, the metabolic syndrome and diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[14] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[15] D. Ollendorf,et al. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. , 2004, MedGenMed : Medscape general medicine.
[16] P. Rochon,et al. Exploring the Association Between Atypical Neuroleptic Agents and Diabetes Mellitus in Older Adults , 2003, Pharmacotherapy.
[17] S. Madhusoodanan,et al. Hyperglycemia and Hypertriglyceridemia in Real World Patients on Antipsychotic Therapy , 2003, American journal of therapeutics.
[18] H. Nasrallah,et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. , 2003 .
[19] K. Melkersson,et al. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses , 2003, Psychopharmacology.
[20] S. Chong,et al. Diabetes Mellitus and Impaired Glucose Tolerance in Patients with Schizophrenia , 2003, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[21] D. Umbricht,et al. Atypical antipsychotics in the treatment of schizophrenia. , 2003, Swiss medical weekly.
[22] J. Lieberman,et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. , 2003, The American journal of psychiatry.
[23] J. Caro,et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. , 2002, The Journal of clinical psychiatry.
[24] H. Nasrallah,et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. , 2002, The Journal of clinical psychiatry.
[25] J. Ananth,et al. Atypical Antipsychotic Drug Use and Diabetes , 2002, Psychotherapy and Psychosomatics.
[26] Julie Kreyenbuhl,et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study , 2002, BMJ : British Medical Journal.
[27] W. Regenold,et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. , 2002, Journal of affective disorders.
[28] Jonathan M. Meyer. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. , 2002, The Journal of clinical psychiatry.
[29] Z. Zhao,et al. PMH6 RISK OF DIABETES FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS , 2002 .
[30] Robert Rosenheck,et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. , 2002, The American journal of psychiatry.
[31] D. Jeste,et al. Phenomenology of and Risk Factors for New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated with Atypical Antipsychotics: An Analysis of 45 Published Cases , 2002 .
[32] Stephan Arndt,et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. , 2001, Archives of general psychiatry.
[33] Douglas G Altman,et al. Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.
[34] B. Kang,et al. The effect of clozapine on blood glucose metabolism , 2001, Human psychopharmacology.
[35] I. Olkin,et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .
[36] Mark Woodward,et al. Epidemiology: Study Design and Data Analysis , 1999 .
[37] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[38] O. Spigset,et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. , 1998, The Journal of clinical psychiatry.
[39] A. Amos,et al. The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010 , 1997, Diabetic medicine : a journal of the British Diabetic Association.
[40] A R Jadad,et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. , 1995, Controlled clinical trials.
[41] A. B. Prasad,et al. British National Formulary , 1994 .
[42] M. First,et al. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. , 1992, Archives of general psychiatry.
[43] A. B. Hill. The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.
[44] Simon Davies,et al. Epidemiology: Study Design and Data Analysis (2nd ed.) , 2006 .
[45] N. Sicolo,et al. Effect of chlorpromazine on blood glucose and plasma insulin in man , 2004, European Journal of Clinical Pharmacology.
[46] A. Colotto,et al. Antipsicotici e implicazioni metaboliche: Valutazione sulla casistica dell'U.O. di Psichiatria di Aosta , 2003 .
[47] D. Henderson. Atypical Antipsychotic-Induced Diabetes Mellitus , 2002, CNS drugs.
[48] E. Oral,et al. Comparison of the effects of classical and novel antipsychotic drugs on the insulin and glucose metabolisms of patients with schizophrenia and other psychotic disorders , 2002 .
[49] Douglas G. Altman,et al. Systematic Reviews in Health Care , 2001 .
[50] L. Dixon,et al. Prevalence and correlates of diabetes in national schizophrenia samples. , 2000, Schizophrenia bulletin.
[51] P. Decina,et al. Diabetes mellitus in schizophrenic patients. , 1996, Comprehensive psychiatry.